Format

Send to

Choose Destination
Gut Microbes. 2017 Sep 3;8(5):486-492. doi: 10.1080/19490976.2017.1310357. Epub 2017 Apr 6.

Intestinal IgA as a modulator of the gut microbiota.

Author information

1
a Applied Immunology , Nara Institute of Science and Technology , Nara , Japan.
2
b Center for Information Biology , National Institute of Genetics , Shizuoka , Japan.
3
c Yakult Central Institute , Tokyo , Japan.
4
d RIKEN Center for Integrative Medical Sciences (IMS) , Kanagawa , Japan.
5
e Graduate School of Medicine , Chiba University , Chiba , Japan.
6
f Graduate School of Medical Life Science , Yokohama City University , Kanagawa , Japan.
7
g PRESTO, Japan Science and Technology Agency , Saitama , Japan.

Abstract

Accumulating evidence suggests that dysbiosis plays a role in the pathogenesis of intestinal diseases including inflammatory bowel disease (IBD) as well as extra-intestinal disorders. As a modulator of the intestinal microbiota, we isolated a mouse monoclonal IgA antibody (clone W27) with high affinities for multiple commensal bacteria, but not for beneficial bacteria such as Lactobacillus casei (L. casei). Via specific recognition of an epitope in serine hydroxymethyltransferase (SHMT), a bacterial metabolic enzyme, W27 IgA selectively inhibited the in vitro growth of bound bacteria, including Escherichia coli (E. coli), while having no effect on unbound beneficial bacteria such as L. casei. By modulating the gut microbiota in vivo, oral administration of W27 IgA effectively prevented development of colitis in several mouse models. Here we discuss how intestinal IgA modulates the gut microbiota through recognition of SHMT.

KEYWORDS:

AID; IgA; dysbiosis; gut microbiota; inflammatory bowel disease; monoclonal antibody

PMID:
28384049
PMCID:
PMC5628655
DOI:
10.1080/19490976.2017.1310357
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center